Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ViatrisHAM:VIA -0.01%66 Debt-to-Equity is 0.94 as of Jun. 2026, which is 14% below its 10-year median of 1.09. GuruFocus rates HAM:VIA with a GF Score™ of 66/100 and a GF Value™ of €9.86 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 812 Drug Manufacturers companies, Viatris ranks worse than 83.74% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Viatris's Debt-to-Equity or its related term are showing as below:
HAM:VIA'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.77 Med: 1.09 Max: 1.4
Current: 0.94
During the past 13 years, the highest Debt-to-Equity Ratio of Viatris was 1.40. The lowest was 0.77. And the median was 1.09.
HAM:VIA's Debt-to-Equity is ranked worse than 83.74% of 812
companies
in the Drug Manufacturers industry
Industry Median: 0.275
vs HAM:VIA: 0.94
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Viatris Debt-to-Equity Related Terms
Viatris Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Viatris's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HAM:VIA vs UTHR, NBIX, ELAN: Debt-to-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Viatris's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viatris Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Viatris's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Viatris's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Viatris (HAM:VIA) has a Debt-to-Equity of 0.94 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Viatris and its competitors. This is 14% below median its historical median of 1.09. Over the past decade, Viatris' Debt-to-Equity has ranged from 0.77 to 1.40. According to the industry distribution chart, Viatris ranks #680 out of 812 companies in the Drug Manufacturers industry, placing it in the top 83.7%.
Is Viatris' Debt-to-Equity too high?
Viatris' current Debt-to-Equity of 0.94 is 14% below median its 10-year median of 1.09. Over the past 10 years, this metric has ranged from a low of 0.77 to a high of 1.40. The Drug Manufacturers industry median Debt-to-Equity is 0.28. Viatris' value of 0.94 is 241.8% above this industry median. Based on the distribution chart, Viatris ranks #680 out of 812 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Viatris has a GF Score™ of 66/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Viatris' Debt-to-Equity compare to UTHR and NBIX?
According to the Drug Manufacturers industry distribution chart, Viatris ranks #680 out of 812 companies for Debt-to-Equity. This places Viatris in the lower half of its industry. The industry median Debt-to-Equity is 0.28. Viatris' value of 0.94 is 241.8% above this benchmark. Historically, Viatris' own Debt-to-Equity has ranged from 0.77 to 1.40 over the past decade. While the company's 10-year median is 1.09 vs. the industry median of 0.28, Viatris has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.28, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Viatris's current Debt-to-Equity of 0.94 is 241.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Viatris and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Viatris's current Debt-to-Equity is 0.94, which is 14% below median its own 10-year median of 1.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viatris stock overvalued right now?
Based on GuruFocus' analysis, Viatris (HAM:VIA) is currently considered Significantly Overvalued. The stock's GF Value™ is €9.86, compared to a current price of €14.05 — trading 42.5% above its estimated fair value. The current Debt-to-Equity is 0.94, which is 14% below median its 10-year median of 1.09 and 241.8% above the Drug Manufacturers industry median of 0.28. Viatris' overall GF Score™ is 66/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Viatris (HAM:VIA), the current Debt-to-Equity is 0.94 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Viatris (HAM:VIA) Overvalued in 2026?
Based on GuruFocus' analysis, Viatris stock appears to be overvalued.
The current stock price of €14.05 is trading 42.5% above its estimated GF Value™ of €9.86.
GuruFocus considers Viatris to be Significantly Overvalued.
Key valuation signals for HAM:VIA:
Debt-to-Equity: 0.94 (14% below median its 10-year median of 1.09)
GF Value™: €9.86 vs. price of €14.05 (42.5% above fair value)
Industry Position: 241.8% above the Drug Manufacturers median (#680 of 812)
No single metric tells the full story. See the HAM:VIA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
66GF Score
Get the complete analysis for HAM:VIA
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:VIA has been successfully added to your 
